Skip to main content

Table 1 Baseline characteristics of 172 eligible and evaluable patients

From: Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland

CharacteristicTotal, n = 172
Age at diagnosis (years)
 Median (IQR)55.2 years (46.8–63.5 years)
Gender
 Female96 (54.2%)
 Male81 (45.7%)
Soft tissue sarcoma subtype
 Leiomyosarcoma75 (43.6%)
 Liposarcoma19 (11.0%)
 Undifferentiated pleomorphic sarcoma13 (7.6%)
 Synovial sarcoma10 (5.8%)
 Myxofibrosarcoma8 (4.7%)
 Solitary fibrous tissue6 (3.5%)
 Angiosarcoma5 (2.9%)
 Malignant peripheral nerve sheath tumour5 (2.9%)
 Soft tissue sarcoma (NOS)5 (2.9%)
 High grade pleomorphic sarcoma (NOS)4 (2.3%)
 Spindle cell sarcoma (NOS)3 (1.7%)
 Extra skeletal myxoid chondrosarcoma3 (1.7%)
 Endometrial stromal sarcoma2 (1.2%)
 Adenosarcoma2 (1.2%)
 PEComa1 (0.6%)
 Intimal sarcoma1 (0.6%)
Sites of metastatic disease
 Lung88 (51.2%)
 Liver31 (18.0%)
 Soft tissue25 (14.5%)
 Bone21 (12.2%)
 Pelvis14 (8.1%)
 Abdominal13 (7.6%)
 Peritoneal11 (6.4%)
 Lymph nodes4 (2.3%)
 Cardiac3 (1.7%)
 Intracranial3 (1.7%)
 Renal2 (1.2%)
 Pancreas1 (0.6%)
 Unknown39 (22.7%)